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Moreover, everolimus-eluting stents (EES) have not been compared with early generation
sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) in patients with LM disease.
Methods: Out of 12,339 consecutive patients, 11,941 completed last follow-up. 410
(3.4%) patients that underwent LM treatment (177 treated with EES and 233 with
SES/PES) were compared with 11,531 (96.6%) patients that underwent non-LM treat-
ment (3,924 treated with EES and 7,607 with SES/PES). In addition, clinical outcomes
were stratified by stent type among LM and non-LM patients, respectively. Adjustment
was performed with inverse probability of treatment weighting. Primary endpoint was a
composite of cardiac death, myocardial infarction (MI), and target-vessel revasculariza-
tion (TVR).
Results: At baseline, LM patients were older, had more frequently renal failure,
LVEF30%, cardiogenic shock, and smoking habits, and less frequently ACS compared
with non-LM patients. At 4 years, LM patients had a higher risk of the primary endpoint
compared with non-LM patients (34.7% vs 21.5%; HR 1.83, 95% CI 1.52-2.21). This was
mainly driven by a higher risk of cardiac death (18.9% vs 7.3%; HR 2.96, 95%CI
2.28-3.84), whereas no significant differences were observed for MI (4.7% vs 5.4%; HR
0.93, 95% CI 0.52-1.65) and TVR (17.5% vs 14.0%; HR 1.31, 95% CI 0.99-1.73).
Stratification of the primary endpoint by stent type showed a risk reduction with the use
of EES compared with early generation SES/PES. This risk reduction was numerical
among LM patients (30.2% vs 36.8%; HR 0.90, 95% CI 0.62-1.31) and met statistical
significance among non-LM patients (18.5% vs 23.2%; HR 0.73, 95% CI 0.66-0.81), with
no interaction between EES use and LM treatment (p-interaction0.74).
Conclusions: LM patients have impaired clinical outcomes compared with non-LM
patients during long-term follow-up, mainly due to a higher risk of cardiac death. Absence
of significant interaction between EES use and LM treatment suggests that EES use has
comparable impact on clinical outcomes in LM and non-LM patients.
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Background: Current guidelines recommend coronary artery bypass graft surgery
(CABG) when treating significant de novo LM stenosis; however, percutaneous coronary
intervention (PCI) has a Class IIb indication for unprotected left main coronary artery
(ULMCA). This analysis will compare the 5-year clinical outcomes in PCI- and
CABG-treated LM patients in the SYNTAX trial.
Methods: In the SYNTAX trial, patients (N1800) with left main and/or 3-vessel
coronary artery stenoses were randomized to receive either PCI with TAXUS Express
paclitaxel-eluting stents (PES) or CABG. The unprotected LM cohort (N705) was a
predefined subset.
Results: Four-year MACCE and the composite of death/stroke/MI were similar in
ULMCA- PCI and CABG-treated patients (Table). Stroke was significantly increased in
the CABG group and repeat revascularization was increased in the PCI arm at 4 years
(Table). MACCE was similar between groups in patients with low or intermediate
SYNTAX Scores (0-32: 29.0% vs 27.6%, p0.65) but significantly increased in PCI
patients with high scores (33: 26.3% vs 42.6%, p0.003).
Adverse Event Rates in the LM cohort at 4 years
CABG
(n348)
PCI
(n357)
CABG
(n348)
PCI
(n357)
MACCE 27.8% 33.2% Stroke 4.3% 1.5%
Death/
Stroke/MI
17.7% 17.1% MI 4.8% 7.2%
Death 11.2% 11.4% Repeat
Revascularization
14.6% 23.5%
MACCE: Major adverse cardiac and cerebrovascular events including all-cause
death, stroke, myocardial infarction, repeat revascularization. Time-to-event
rates at 4 years.
p0.05 from log-rank or chi-square test.
Conclusions: At 4 years, no difference in overall MACCE was found between treatment
groups. There was an advantage of PCI in stroke and a reduced need for repeat
revascularization with CABG. SYNTAX and other recent studies of LM disease suggest
that in some patients (those with less complex lesions as defined by low or intermediate
SYNTAX Scores), PCI using drug-eluting stents may be as effective but less invasive than
CABG. CABG should be used for patients with more complex anatomical disease (high
SYNTAX Scores). Five-year data will be available at the time of presentation.
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Background: In patients with severe, multivessel coronary disease, coronary artery
bypass grafting (CABG) has been considered the standard of care. We will present 5-year
outcomes in the 3VD subgroup of patients in SYNTAX.
Methods: SYNTAX is a randomized clinical trial with nested registries. A cardiac
surgeon and interventional cardiologist screened consecutive patients with de novo 3VD
and/or LM disease. After informed consent, the patient was randomized if suitable for
equivalent revascularization with either treatment; otherwise, they were enrolled in a
nested registry. Analysis of the 3VD patient cohort was prespecified.
Results: In the 3VD subgroup at 4 years, MACCE was significantly higher in patients
with percutaneous coronary revascularization (PCI) compared with CABG patients. The
rates of composite death/stroke/MI, death, MI, and repeat revascularization were in-
creased in PCI patients; however, stroke was similar between groups at 4 years (Table).
Partitioning 3VD subgroup patients by SYNTAX Score tercile demonstrated similar
MACCE in patients with low scores (0-22: CABG 24.7% vs PCI 30.4%, p0.27);
whereas both MACCE and mortality were increased in PCI patients with intermediate
scores (23-32: 17.9% vs 33.3%, p0.001 and 6.8% vs 12.7%, p0.048), and with scores
33 (21.2% vs 37.9%, p0.001 and 6.5% vs 14.5%, p0.02). Five-year outcomes will
be available at the time of the presentation.
Adverse Event Rates at 4 years in the 3VD cohort
CABG
(n549)
PCI
(n546)
CABG
(n549)
PCI
(n546)
MACCE 21.0% 33.7% Stroke 3.4% 2.8%
Death/
Stroke/MI
12.6% 18.6% MI 3.3% 9.0%
Death 7.3% 11.9% Repeat
Revascularization
10.2% 22.8%
MACCE: Major adverse cardiac and cerebrovascular events including all-cause
death, stroke, myocardial infarction, repeat revascularization. Time-to-event
rates at 4 years.
p0.05 from log-rank or chi-square test.
Conclusions: This will be the first presentation of the final 5-year outcomes in the 3VD
patient population of SYNTAX. Four-year results suggest that CABG remains the
standard of care for patients with complex lesions (intermediate or high SYNTAX Score).
With less complex disease (low SYNTAX Scores), PCI is an acceptable revascularization
alternative.
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Background: The effectiveness of 1st generation durable polymer drug-eluting stents
comes at the expense of delayed arterial healing and subsequent late adverse events such
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as stent thrombosis. The Biolimus A9™ eluting stent platform (BES) releases biolimus
from an abluminal biodegradable polymer, fully absorbed after 6-9 months. The
LEADERS trial assessed the safety and efficacy of BES with an established stent platform
releasing sirolimus from a durable polymer (SES) in a large scale, all-comers, non-
inferiority trial. We report the 5 year follow-up and final report of the LEADERS study.
Methods: LEADERS is a multi-center, randomized, assessor-blind, non-inferiority trial
performed at 10 European sites in an all-comers, “real world” patient population. A total
of 1,707 patients were enrolled and randomized 1:1 to BES or SES. The primary endpoint
was MACE (a composite of cardiac death, MI, or clinically-indicated TVR) at 9 months.
Secondary endpoints include death, cardiac death, MI, ST (ARC defined), TLR and TVR.
All patients are followed up to 5 years.
Results: 1707 patients were allocated to BES (857) and SES (850) patients. At 4 years,
there was a clinical follow-up rate of over 96%, at which time the risk of MACE was
lower in patients treated with BES than in those treated with SES (18.7% vs. 22.6%: p
0.050). The RR of definite ST was 0.62 (p0.09), which was largely attributed to a lower
risk of very late definite ST between years 1 and 4 in the BES compared to the SES group
(RR 0.20, p0.004) demonstrating 80% relative risk reduction. An analysis of the
correlation between MACE and definite stent thrombosis events showed that the benefit
in favor of BES in terms of MACE was largely driven by a lower risk of MACE
associated with definite VLST beyond the first year of follow-up.The 5-year analysis of
LEADERS trial is ongoing.
Conclusions: Biodegradable polymer BES are non-inferior to durable polymer SES, and
by reducing the risk of cardiac events associated with VLST, might improve long-term
clinical outcomes. LEADERS final 5-year follow-up results will be reported for the 1st
time during this presentation.
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Background: XIENCE V USA is a prospective, multicenter, single-arm, FDA required
condition of approval study designed to examine the performance of XIENCE V®
Everolimus Eluting Coronary Stent System (XIENCE V, Abbott Vascular, Santa Clara,
CA) in a real-world all-comer population. The safety and effectiveness of XIENCE V in
real world have been demonstrated previously with low rates of target lesion revascular-
ization (TLR), cardiac death, MI and stent thrombosis (ST) at both 1 and 2 years. Whether
these results of the XIENCE V are sustained at 3 years has not been reported, particularly
regarding the very late ST.
Methods: A total of 5020 patients (1871 [37%] standard risk, and 3149 [63%] extended
risk) were included in the long term follow-up cohort of the study. All clinical endpoint
events were adjudicated independently by the Clinical Events Committee.
Results: Clinical Outcomes through 3 years in the overall population as well as the key
subgroups for the extended risk population were shown in the table below. About 93% of
patients remained in the study at 3 years. The overall very late ST between 1 and 3 years
was 0.23% with 53.1% patients remained on dual antiplatelet therapy (DAPT) at 3 years.
Conclusions: Low event rates were sustained through 3 years for the overall population,
with higher rates observed in certain high risk subgroups than the standard risk population
as expected. Despite that half of the patients were off DAPT at 3 years, the very late ST
between 1 and 3 years remained low as 0.23%. These results demonstrate continued safety
and effectiveness of the XIENCE V in a highly complex, real-world patient population
through 3 years.
XIENCE V USA Clinical Outcomes Through Three Years
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1.16%
(52)
0.41%
(7)
1.62%
(45)
1.57%
(9)
2.58%
(12)
1.55%
(24)
1.86%
(11)
2.25%
(10)
3.13%
(11)
2.41%
(8)
0.92%
(1)
Cardiac
Death and
ARC MI
11.5%
(547)
7.4%
(131)
14.0%
(416)
15.8%
(97)
23.3%
(123)
15.2%
(254)
14.6%
(91)
11.6%
(55)
14.6%
(54)
15.5%
(55)
11.0%
(13)
Cardiac
Death and
WHO MI
6.6%
(311)
3.6%
(64)
8.4%
(247)
9.7%
(59)
14.9%
(79)
8.9%
(148)
7.9%
(49)
7.2%
(34)
7.3%
(27)
9.3%
(33)
5.9%
(7)
TLF (ARC) 15.5%
(735)
9.8%
(175)
18.9%
(560)
18.1%
(111)
26.1%
(138)
20.2%
(337)
20.8%
(130)
16.3%
(77)
27.8%
(103)
18.9%
(67)
19.5%
(23)
TLF (WHO) 13.1%
(621)
8.1%
(144)
16.1%
(477)
15.4%
(94)
21.2%
(112)
17.4%
(290)
16.9%
(105)
13.8%
(65)
25.9%
(96)
16.1%
(57)
16.9%
(20)
TLR 9.0%
(426)
5.8%
(104)
10.9%
(322)
9.5%
(58)
11.0%
(58)
11.7%
(196)
12.8%
(80)
9.3%
(44)
22.9%
(85)
10.1%
(36)
14.4%
(17)
Data are % (N).
ARC MI definition: elevation of troponin or CKMB  3 URL for periprocedual PCI,  5 URL for periprocedual CABG,
and  1 URL for spontaneous MI.
WHO MI definition: QMI per ECG or elevation of CK  2 URL with elevated CKMB in the absence of new pathological
Q waves.
TLF  target lesion failure, a composite of cardiac death, MI attributed to target vessel, and TLR; ST  stent
thrombosis; MI  myocardial infarction; ARC  Academic Research Consortium; WHO  world health organization;
TLR  target lesion revascularization; AMI  acute myocardial infarction; ISR in-stent restenosis; CTO  chronic
total occlusion
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Background: Drug-eluting stents reduce the rate of TLR compared with bare metal
stents. However, there is still concern of an increased incidence of VLST potentially
related to the durable polymer. The BioFreedom™ stent (BFD) releases Biolimus A9™,
without the use of a polymer or binder. This trial aims to demonstrate the safety and
effectiveness of the BioFreedom biolimus-eluting stent as compared to the Taxus
Liberté™ pactilaxel-eluting stent (PES).
Methods: The BioFreedom FIM trial is a prospective, multi-center, randomized,
single-blind study. 182 patients were enrolled and randomized to BFD Standard Dose
(SD, 15.6 g/mm), or BFD Low Dose (LD, 7.8 g/mm), or Taxus Liberté™ DES at 4
sites in Germany. The first 75 patients received angio and IVUS FU at 4 months (1st
cohort), the remaining patients received angio and IVUS FU at 12 months (2nd cohort).
The primary endpoint was in-stent Late Loss (LL) at 12 months. The secondary endpoints
are IVUS neointimal volume at 4 months; MACE (death, MI, emergent Bypass or
clinically-driven TLR) and ST rates (ARC defined) at 30 days, 4 and 12 months, 2, 3, 4
and 5 years.
Results: The in-stent LL was non inferior in BFD SD vs.Taxus (Pnon-inferiority 
0.001) and trended towards superiority with medians of 0.17mm [0.09, 0.39] vs. 0.35mm
[0.22, 0.57] for BFD SD compared to Taxus (Psup0.11) at 12 months. At 2 years, the
clinical FU for all patients was 99%. The BFD SD showed numerically lower rates of
MACE (BD SD 6.8% vs. PES 10.0%) and TLR (BFD SD 3.4% vs. PES 6.7%). No stent
thrombosis was seen in any groups up to 2 year. The 3-year clinical evaluation is ongoing.
Conclusions: This First-In-Man study has proven non-inferiority (with trend towards
superiority) of the BioFreedom (polymer free stent versus TAXUS Liberté in the primary
endpoint of in-stent LL. The safety and efficacy characteristics were comparable up to 2
years follow up with numerically lower MACE and TLR for BioFreedom. The
BioFreedom FIM 3-year follow-up results will be reported for the 1st time during this
presentation.
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